May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Doxycycline-Mediated Inhibition of Matrix Metalloproteinase Types 2 and 9, and Choroidal Neovascularization
Author Affiliations & Notes
  • S. Samtani
    National Eye Institute, Bethesda, Maryland
    Biological Imaging Core,
  • J. Amaral, M.D.
    National Eye Institute, Bethesda, Maryland
    LRCMB,
  • S. P. Becerra Ph.D.
    National Eye Institute, Bethesda, Maryland
    LRCMB,
  • R. N. Fariss Ph.D.
    National Eye Institute, Bethesda, Maryland
    Biological Imaging Core,
  • Footnotes
    Commercial Relationships  S. Samtani, None; J. Amaral M.D., None; S.P. Becerra Ph.D., None; R.N. Fariss Ph.D., None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5415. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Samtani, J. Amaral, M.D., S. P. Becerra Ph.D., R. N. Fariss Ph.D.; Doxycycline-Mediated Inhibition of Matrix Metalloproteinase Types 2 and 9, and Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5415. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Doxycycline is a broad spectrum antibiotic and has been shown to have certain anti-angiogenic properties. Matrix metalloproteinases (MMPs) are extracellular matrix endopeptidases that act as pro-angiogenic factors, degrading substrates such as collagens and gelatin. We investigated the effect of doxycycline on choroidal neovascularization (CNV), and its regulation of MMP-2 and MMP-9 and anti-angiogenic pigment epithelium derived factor (PEDF).

Methods: : Doxycycline was orally administered to Brown Norway rats at 500, 50, 5, and 0.5 mg/kg/day, and non treated animals were used as controls. After 7 days of doxycycline treatment, experimental CNV was induced with laser. Seven days post-induction, animals were euthanized, blood samples collected and serum separated. Eyes were collected from experimental and control animals for confocal analysis. The RPE/choroid was flat-mounted, labeled with isolectin IB4 and CNV volumes were determined using confocal microscopy and VolocityTM software. Protein levels of MMP-2, MMP-9, and PEDF in serum were determined using Enzyme Linked ImmunoSorbent (ELISA) assays. MMP catalytic activity was determined in solution assays using a fluorogenic MMP peptide substrate, and in in situ assays using gelatin as substrate embedded in polyacrylamide zymography gels.

Results: : CNV volumes decreased logarithmically with doxycycline treatment. A dosage of 500 mg/kg/day showed a 70 % inhibition of CNV, compared to control animals. Doxycycline elevated the levels of PEDF in the serum. ELISA assays show that the pro- and active forms of MMP-2 and MMP-9 in serum did not change significantly with doxycycline. Doxycycline inhibited the activity of MMP-2 and MMP-9 in solution assays and zymography.

Conclusions: : Doxycycline inhibited the progression of experimental CNV, elevated the serum levels of PEDF protein and inhibited the catalytic activity of MMP-2 and MMP-9 without affecting their protein levels. These results suggest a potential therapeutic role for doxycycline as an anti-angiogenic agent.

Keywords: age-related macular degeneration • choroid: neovascularization • extracellular matrix 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×